Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$59.06 - $75.72 $30,711 - $39,374
-520 Reduced 11.0%
4,206 $311,000
Q3 2023

Nov 02, 2023

SELL
$65.94 - $99.04 $303,389 - $455,683
-4,601 Reduced 49.33%
4,726 $322,000
Q2 2023

Jul 17, 2023

SELL
$62.68 - $95.05 $469,911 - $712,589
-7,497 Reduced 44.56%
9,327 $875,000
Q4 2022

Feb 09, 2023

BUY
$30.35 - $53.15 $111,020 - $194,422
3,658 Added 27.78%
16,824 $833,000
Q3 2022

Nov 10, 2022

SELL
$31.97 - $49.37 $16,944 - $26,166
-530 Reduced 3.87%
13,166 $428,000
Q2 2022

Aug 03, 2022

SELL
$35.61 - $76.23 $14,742 - $31,559
-414 Reduced 2.93%
13,696 $539,000
Q1 2022

May 03, 2022

BUY
$57.56 - $82.54 $235,247 - $337,340
4,087 Added 40.78%
14,110 $987,000
Q4 2021

Feb 01, 2022

BUY
$72.5 - $100.68 $57,130 - $79,335
788 Added 8.53%
10,023 $780,000
Q3 2021

Oct 08, 2021

BUY
$90.24 - $124.05 $117,402 - $161,389
1,301 Added 16.4%
9,235 $881,000
Q2 2021

Aug 05, 2021

BUY
$93.66 - $139.27 $132,528 - $197,067
1,415 Added 21.71%
7,934 $986,000
Q1 2021

Apr 14, 2021

BUY
$116.57 - $155.01 $659,786 - $877,356
5,660 Added 658.91%
6,519 $859,000
Q1 2021

Apr 13, 2021

SELL
$116.57 - $155.01 $536,921 - $713,976
-4,606 Reduced 84.28%
859 $113,000
Q4 2020

Feb 08, 2021

SELL
$99.61 - $142.12 $1.17 Million - $1.67 Million
-11,767 Reduced 68.29%
5,465 $724,000
Q1 2020

May 13, 2020

BUY
$37.9 - $104.44 $504,828 - $1.39 Million
13,320 Added 340.49%
17,232 $161,000
Q4 2019

Feb 12, 2020

BUY
$77.66 - $99.74 $23,453 - $30,121
302 Added 8.37%
3,912 $362,000
Q3 2019

Nov 07, 2019

BUY
$90.37 - $122.49 $326,235 - $442,188
3,610 New
3,610 $326,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track F Dx Advisors, Inc. Portfolio

Follow F Dx Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on F Dx Advisors, Inc. with notifications on news.